JAK inhibitor access landscape: Rinvoq, Xeljanz, Olumiant, Leqselvi, and Cibinqo in 2026

Janus kinase (JAK) inhibitors are oral small molecules that block cytokine signaling through the JAK-STAT pathway. Six JAK inhibitors are FDA-approved for immune-mediated conditions in the US: Rinvoq (upadacitinib), Xeljanz (tofacitinib), Olumiant (baricitinib), Cibinqo (abrocitinib), Litfulo (ritlecitinib), and Leqselvi (deuruxolitinib). All carry a class-wide FDA boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis, based on the ORAL Surveillance post-marketing safety trial of tofacitinib in rheumatoid arthritis. This boxed warning fundamentally shapes payer coverage, step therapy requirements, and the prescribing hierarchy relative to biologics.

This landscape guide is for prescribers, access teams, pharmacists, and payer professionals who need a cross-JAK view of coverage, prior authorization, safety-driven access restrictions, and cost.

FDA-approved JAK inhibitors at a glance

Common FDA-approved indications

The boxed warning and its access implications

In September 2021, the FDA required class-wide boxed warnings for Xeljanz, Olumiant, and Rinvoq after the ORAL Surveillance trial demonstrated higher rates of MACE, malignancy, thrombosis, and all-cause mortality with tofacitinib compared with TNF inhibitors in RA patients aged 50 and older with at least one cardiovascular risk factor. The FDA extended the warning to all JAK inhibitors, including newer agents not studied in similar safety trials, based on shared mechanisms of action.

Key regulatory consequences:

1. RA, PsA, and AS: All JAK inhibitors are now limited to patients who have had an inadequate response or intolerance to one or more TNF inhibitors. First-line use before a TNF inhibitor is not recommended by the FDA

2. UC and CD: Rinvoq and Xeljanz are indicated for patients who have had an inadequate response or intolerance to one or more TNF inhibitors

3. Atopic dermatitis: Rinvoq and Cibinqo are labeled for patients whose disease is not adequately controlled with other systemic drug products, including biologics

4. Alopecia areata: Olumiant, Litfulo, and Leqselvi do not carry the same TNF-first sequencing requirement because AA is not treated with TNF inhibitors. However, the boxed warning still applies

This regulatory framework means that for most immunology indications, payers require documented TNF inhibitor failure before approving a JAK inhibitor. This creates a clear sequencing hierarchy: conventional DMARDs, then TNF inhibitor or other biologic, then JAK inhibitor.

Formulary placement and prior authorization

JAK inhibitors are typically specialty-tier drugs with mandatory prior authorization. The TNF-first requirement is enforced through PA criteria at virtually all major payers.

Commercial insurance

Key PA criteria patterns for RA, PsA, and AS across payers:

1. Diagnosis of moderate-to-severe active disease

2. Trial and failure of conventional DMARDs (methotrexate, leflunomide, sulfasalazine) for minimum 3 months

3. Trial and failure of one or more TNF inhibitors

4. Some payers require trial and failure of additional biologics (e.g., Orencia, ustekinumab) before JAK inhibitor approval

5. Not used in combination with other biologics or potent immunosuppressants

6. Prescribed by or in consultation with a rheumatologist

For atopic dermatitis, Cigna's 2026 policy requires:

• Moderate-to-severe AD with at least 10% BSA involvement or significant areas (face, hands, groin)

• Trial and failure of topical therapies and dupilumab or other biologic

• Prescribed by or in consultation with a dermatologist, allergist, or immunologist

For alopecia areata (Olumiant, Litfulo, Leqselvi):

• Diagnosis of severe alopecia areata with at least 50% scalp hair loss

• Exclusion of other alopecia causes

• No concurrent use of other JAK inhibitors or biologics

• Olumiant PA at UHC requires trial and failure of TWO TNF inhibitors AND TWO additional biologics (Cimzia, Enbrel, Humira/biosimilar, Rinvoq, Simponi, Xeljanz) PLUS Orencia

Medicare Part D

No JAK inhibitors are currently subject to IRA-negotiated pricing. Key Medicare access points:

• JAK inhibitors are covered under Medicare Part D with prior authorization

• The Part D out-of-pocket cap is $2,100 in 2026

• AbbVie reports that 65% of Rinvoq rheumatology Medicare patients are covered through the Part D Extra Help (LIS) program, where patients pay $12.65 or less per prescription in 2026

• Patients can opt into the Medicare Prescription Payment Plan (MPPP) to spread costs across the year

Medicaid

State Medicaid programs cover JAK inhibitors with restrictive PA criteria:

• Documented diagnosis and severity

• Step therapy through conventional DMARDs and one or more TNF inhibitors is standard

• Some states require trial and failure of multiple biologics before JAK inhibitor approval

• Preferred drug lists may favor older agents (Xeljanz) or specific products based on rebate arrangements

• Rinvoq is increasingly preferred over Xeljanz on many Medicaid PDLs due to broader indications and AbbVie's contracting position

Generic competition timeline

Generic tofacitinib is expected to become more broadly available in 2026 as patent exclusivity fully winds down. This will be the first generic JAK inhibitor on the US market and is expected to create significant pricing pressure, particularly for RA and UC indications.

Prior authorization checklist

When submitting prior authorization for any JAK inhibitor, prepare:

1. Diagnosis documentation: ICD-10 code (M05.x/M06.x for RA, L40.50/L40.59 for PsA, M45.x for AS, K51.x for UC, K50.x for CD, L20.x for AD, L63.x for AA)

2. Disease severity: DAS28, CDAI, or similar scoring for RA; BSA/EASI for AD; SALT score for AA

3. TNF inhibitor failure: Document specific TNF inhibitors tried, duration, reason for discontinuation (inadequate response, adverse event, contraindication)

4. Conventional DMARD failure: Document methotrexate or other conventional agents tried and failed

5. TB screening: Negative tuberculosis test prior to initiation

6. Cardiovascular risk assessment: Document smoking status, cardiovascular risk factors, and absence of prior MACE

7. Specialist involvement: Prescribed by or in consultation with appropriate specialist

8. Combination therapy check: Confirm no concurrent biologics, other JAK inhibitors, or potent immunosuppressants

Common ICD-10 codes for JAK inhibitor PA:

Cost and copay programs

Commercial copay programs

WAC pricing context

Patient assistance

Each manufacturer offers patient assistance programs for qualifying uninsured or underinsured patients. AbbVie's Rinvoq program reports ~99% preferred combined commercial and Medicare Part D coverage after trial of one TNF inhibitor. Leqselvi requires CYP2C9 genotyping before initiation; the cost of this test is covered by Sun Pharma through LabCorp or Quest.

Rinvoq market position

Rinvoq has emerged as the commercially dominant JAK inhibitor due to its broadest indication portfolio (RA, PsA, AS, nr-axSpA, UC, CD, AD, GCA, PJIA) and AbbVie's contracting strategy. Key access data points:

• ~99% preferred combined commercial and Medicare Part D coverage after trial of 1 TNFi

• #1 first-line biologic by rheumatologists in PsA (per AbbVie internal data, 2025)

• ~65% of Rinvoq rheumatology Medicare patients use the Part D Extra Help program

• AbbVie is pursuing regulatory differentiation from the class-wide boxed warning, with 2026 long-term safety data readouts expected to support label modifications

The 2026 data readouts for Rinvoq are particularly significant: AbbVie is accumulating long-term safety data in atopic dermatitis and other indications that could potentially support a regulatory conversation about individualized labeling, if the data demonstrates a differentiated safety profile compared with tofacitinib.

What to monitor next

• Generic tofacitinib launch (2026): The first generic JAK inhibitor will significantly reduce costs for RA and UC patients. Payers are expected to rapidly shift formularies to generic tofacitinib and may impose step therapy requiring generic tofacitinib before Rinvoq or Olumiant

• Rinvoq safety data readouts (2026): AbbVie's long-term safety data in AD and potential label differentiation from the class-wide boxed warning could reshape payer positioning and prescribing hierarchy

• Olumiant label evolution: Watch for any indication expansions or safety updates

• Leqselvi market uptake: As the newest JAK inhibitor for AA (approved July 2024), monitor payer adoption and PA criteria, particularly the CYP2C9 genotyping requirement

• Payer step therapy consolidation: Watch for Medicaid and commercial plans that require generic tofacitinib before any branded JAK inhibitor once generics are available

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Coverage, formulary placement, and prior authorization criteria vary by plan and change frequently. Always verify current requirements with the patient's specific payer.

Sources

• FDA. FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors (2021). https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death

• UHC. Rinvoq (Upadacitinib) Prior Authorization/Medical Necessity (effective 2/1/2026). https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Med-Nec-Rinvoq-Rinvoq_LQ.pdf

• UHC. Olumiant (Baricitinib) Prior Authorization/Medical Necessity. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/h-p/PA-Med-Nec-Olumiant.pdf

• Cigna. Inflammatory Conditions — Rinvoq/Rinvoq LQ Prior Authorization Policy (reviewed 02/11/2026). https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_444_coveragepositioncriteria_inflammatory_conditions_rinvoq_pa.pdf

• Mass General Brigham Health Plan. Olumiant PA Policy (effective 05/01/2026). https://resources.massgeneralbrighamhealthplan.org/pharmacy/PharmacyPolicies/CommercialPolicies/Olumiant_PA_ComExch_Rx_05.01.2026.pdf

• AbbVie. Rinvoq Access for RA, PsA, AS, nr-axSpA, and GCA. https://www.rinvoqhcp.com/rheumatology/access

• AbbVie. Skyrizi Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761061s024lbl.pdf

• FDA. Xeljanz (Tofacitinib) Prescribing Information (revised 3/2026). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208246s027lbl.pdf

• NAAF. FDA-Approved JAK Inhibitors. https://www.naaf.org/navigation-toolkit/fda-approved-jak-inhibitors

• NAAF. Leqselvi (Deuruxolitinib) FAQ. https://www.naaf.org/leqselvi-deuruxolitinib-faq

• FDA. Leqselvi (Deuruxolitinib) Multi-Discipline Review (2024). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217900Orig1s000MultidisciplineR.pdf

• Healio. FDA Adds Black Box Warning to JAK Inhibitors (2021). https://www.healio.com/news/rheumatology/20210901/fda-adds-black-box-warning-to-jak-inhibitors-cites-heartrelated-issues-cancer-death

• QuickRx. Xeljanz (Tofacitinib) FAQ (April 2026). https://quickrxspecialty.pharmacy/xeljanz-tofacitinib-faq

• GlobalHealth. PA Criteria 2026. https://www.globalhealth.com/media/lgjl5mzh/global-health-commercial_pa_eff_01012026_sof-508.pdf